SecBot SecBot

BHVN

Biohaven Ltd.
NYSE· Pharmaceutical Preparations· Inc. D8· CIK 0001935979 Biotech & Drug Discovery
$13.88 −0.81 (−5.51%)
Oct 23 4:00 PM ET · prev $14.69
Market cap
$2.2B
Mid cap
Consensus
Buy
74% Buy or better · 23 analysts
Median target
🔒 Subscribers only
1 year
−16.4%
from $16.60 · Oct 24
30 days
+5.2%
from $13.19
52-week range
$7.79–18.11
−23% from high · low Nov 10
Avg volume 20D
3.44M
Oct 22 spike 30.51M
Short interest
19.05M
≈12.6% of shares · −6.8%
Days to cover
6.4
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 1 bearish · 3 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 17, 2026
Strongest BULLISH Biohaven entered a strategic licensing agreement with Ono Pharmaceutical for its MoDE pan IgG degrader…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • AnalystsBULLISH

    17 of 23 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −6.8% to 19.05M shares. 6.4 days to cover, ≈12.6% of shares.

  • TrendRANGE

    3% above its 50-day average.

The Street

23 analysts
Buy 74% rate it Buy or better
Strong Buy7Buy10Hold5Sell1Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 23, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Sep 10, 2026HC Wainwright & Co.
REITERATE
REITERATENeutral
Sep 8, 2026RBC Capital
DOWNGRADE
DOWNGRADESector Perform
Aug 12, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Aug 11, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Jun 29, 2026B of A Securities
DOWNGRADE
DOWNGRADEUnderperform
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 14, 2026
Clinical Trial
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
Phase Phase 2 — COMPLETED
Oct 14, 2026
Clinical Trial
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Phase Phase 2 — COMPLETED
Sep 11, 2026
Press release
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in…
Aug 25, 2026
Press release
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University…
Aug 10, 2026
Earnings date
BHVN Q2 2026 Earnings Scheduled — 2026-08-10

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 15, 2026
Gentile Kimberly
SVP, Clinical Operations
AWARD1,000 sh
Apr 28, 2026
GREGORY JULIA P
Director
AWARD68,693 sh
Apr 28, 2026
Antonijevic Irina
Director
AWARD68,693 sh
Apr 28, 2026
HUGIN ROBERT J
Director
AWARD68,693 sh
Apr 28, 2026
CHILDS JOHN W
Director
AWARD68,693 sh
Apr 28, 2026
Heffernan Michael Thomas
Director
AWARD68,693 sh
Apr 28, 2026
Bailey Gregory
Director
AWARD68,693 sh
Apr 28, 2026
Mehta Kishan
Director
AWARD68,693 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
19,053,695
shares short
-6.8%
vs prior settlement
6.4
days to cover
≈12.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Biohaven announced that the FDA accepted for review its resubmitted NDA for troriluzole (Vyglxia) in spinocerebellar…
8-K — Impact 6/10
Oct 15, 2026 SEC
Biohaven entered a strategic licensing agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio…
8-K — Impact 7/10
Sep 15, 2026 Insider
Gentile Kimberly was granted 1,000 shares
SVP, Clinical Operations
Sep 11, 2026 Other
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's par
Sep 10, 2026 SEC
Biohaven disclosed that the FDA issued a partial clinical hold letter on September 4, 2026, pausing new patient…
8-K — Impact 7/10
Apr 28, 2026 Insider
GREGORY JULIA P was granted 68,693 shares
Director
Apr 28, 2026 Insider
Antonijevic Irina was granted 68,693 shares
Director

SecBot reports

11 filings · 4 bullish · 2 bearish · 5 neutral
All BHVN filing & press-release reports (11)